We report three cases of recurrence of giant cell tumor characterized by ossification of surrounding soft tissue. On resection, the ossified rim in the soft tissue masses were pathognomonic of recurrence of giant cell tumor. Knowledge of this findings would help for accurate diagnosis and appropriate treatment.
Bone Neoplasms ; Diagnosis ; Giant Cell Tumors* ; Giant Cells* ; Recurrence*

PURPOSE: To describe the MR characteristics of giant cell tumor of bone. MATERIALS AND METHODS: MR iraagings of 15 cases of pathologically proved giant cell tumor were retrospectively analyzed. Signal intensity and homogeneity, involvement of articular surface, low signal intensity rim around the tumor, cortical disruption and soft tissue involvement were evaluated. RESULTS:Tumor showed low signal intensity on T1 weighted images(93%), inhomogenous high signal on T2 or T2* weighted images(93%) and inhomogeneous enhancing pattern(88%). In 11 cases of giant cell tumor of long bones, all cases showed involvement of articular margin and 10 cases(90%) showed rim of low signal intensity between tumor and normal marrow. Disruption of cortical bone(25%) and soft tissue involevement(7%) were also demonstrated. CONCLUSION: We concluded that giant cell tumor showed characteristic MR findings could be helpful in making correct diagnosis.
Bone Marrow ; Diagnosis ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Retrospective Studies

Giant cell tumor of bone is an uncommon, primary neoplasm that occurs chiefly in the ends of the long bones. Giant cell tumor is rarely encountered in the skull, where it preferentially involves the sphenoid, ethmoid, and temporal bones. Radiographically, there are no characteristic findings which can be regarded as typical of a giant cell tumor. Therefore, the diagnosis must be made by biopsy. This tumor is characterized by benign histologic features, but it can be locally aggressive and can even metastasize. Complete surgical excision is the treatment of choice for giant cell tumor. We have experienced a case of giant cell tumor of the temporal bone which was removed with infratemporal fossa approach type B. So, we report with review of literatures.
Biopsy ; Diagnosis ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Skull ; Temporal Bone*

In this retrospective study, surgical results of four patients with sacral tumors having disparate pathologic diagnoses, who were treated with partial or total sacrectomy and lumbopelvic stabilization were abstracted. Two patients were treated with partial sacral resection and two patients were treated with total sacrectomy and spinopelvic fixation. Fixation methods included spinopelvic fixation with rods and screws in two cases, reconstruction plate in one case, and fresh frozen allografts in two cases. Fibular allografts used for reconstruction accelerated bony union and enhanced the stability in two cases. Addition of polymethyl methacrylate in the cavity in the case of a giant cell tumor had a positive stabilizing effect on fixation. As a result, we can conclude that mechanical instability after sacral resection can be stabilized securely with lumbopelvic fixation and polymethyl methacrylate application or addition of fresh frozen allografts between the rods can augment the stability of the reconstruction.
Allografts ; Diagnosis* ; Giant Cell Tumors ; Humans ; Polymethyl Methacrylate ; Retrospective Studies

Foot ; pathology ; Giant Cell Tumors ; diagnosis ; Humans ; Tendons ; pathology

Giant cell tumor of bone is a locally aggressive benign neoplasm, which is composed of oval or plump, spindle-shaped mononuclear cells and uniformly distributed multinucleated giant cells. Bone or cartilage matrix production by the tumor cells is usually not seen. We present a pathologically proven case of giant cell tumor, arising in the acetabulum and pubic bone, with unusual cartilage matrix production. We also discuss the differential diagnosis from a chondroblastoma as well as a giant cell-rich osteosarcoma.
Acetabulum ; Cartilage* ; Chondroblastoma ; Diagnosis, Differential ; Giant Cell Tumor of Bone ; Giant Cell Tumors* ; Giant Cells* ; Osteosarcoma ; Pubic Bone

OBJECTIVE: The treatment of giant cell tumor (GCT) is mainly performed surgically. However, GCT in spine seems difficult to treat because of the limited surgical accessibility and proximity. In this report, we analyzed the outcome of GCT treatment in spine. METHODS: Between 2000 and 2012, 19 patients received treatment for GCT in spine. Median age at their first diagnosis was 31 years, 10 patients were male, and 9 female. Fourteen tumors were located in the sacrum, 1 in cervical, 1 in thoracic and 3 in lumbar spine. As primary treatment, gross total removal (GTR) was done in 6 patients, and subtotal removal (STR) in 13 patients. Radiation therapy (RT) as an adjuvant therapy was performed in 2 cases in GTR group and 10 cases in STR group. RESULTS: During the follow-up, 7 patients had local recurrence (36.8%). The average period until recurrence after primary treatment was 14 months. No recurrence was detected in GTR group. Recurrence was noted in 7 out of 13 patients who underwent STR. These differences were statistically significant (p=0.024). A median of recurrence free period (RFP) was 84 months. Also average RFP of the RT group was 112 months, and non-RT group was 65 months. These differences were statistically significant (p=0.041). CONCLUSION: Treatment of choice for GCT in spine is a complete removal of tumor without neurological deficits. In case of incomplete removal, radiation therapy may be a useful adjuvant treatment modality.
Diagnosis ; Female ; Follow-Up Studies ; Giant Cell Tumors* ; Giant Cells* ; Humans ; Male ; Radiotherapy ; Recurrence ; Sacrum ; Spine*

We report a case of tenosynovial giant cell tumor with severe bone erosion in the right fifth finger of a 46-year-old man. Throughout this case review, we describe the imaging findings of tenosynovial giant cell tumor with severe bone erosion and review the literatures regarding osseous lesions caused by tenosynovial giant cell tumor and their significance related to the differential diagnosis and patient treatment.
Diagnosis, Differential ; Fingers* ; Giant Cell Tumors* ; Giant Cells* ; Hand ; Humans ; Magnetic Resonance Imaging ; Middle Aged

Plain radrographs of thirty nine patients with giant cell tumor of long bone and CT scans of twenty patients among the thirty patients were reviewed retrospectively to evaluate the frequency and significance of sclerosis of the tumor margin. The sclerosis of the tumor margin was observed on plain radiographs in thirteen patients(33.3%) and they were located either on epiphyseal or on both epiphyseal or metaphyseal portion of the tumor. The authors concluded that the giant cell tumor should not be excluded from the differential entities eventhough the tumor has the marginal sclerosis.
Diagnosis, Differential* ; Giant Cell Tumors* ; Giant Cells* ; Humans ; Retrospective Studies ; Sclerosis* ; Tomography, X-Ray Computed

PURPOSE: Tenosynovial giant cell tumors (TSGCT) can be classified into localized and diffuse types. To identify reliable diagnostic markers for these tumors, we compared clinicopathologic and immunohistochemical features in localized and diffuse type TSGCT. MATERIALS AND METHODS: Clinicopathologic and immunohistochemical studies were perfomed. Thirty cases which had been histologically diagnosed as TSGCT after surgery, at our hospital from 2000 to 2012, were analyzed. RESULTS: There was no statistically significant difference between the groups for gender, age, site, recurrence, symptom (p>0.05). Macrophage colony-stimulating factor (MCSF), CD68, and Ki67 expression was identified in localized and diffuse type TSGCT. But there was no statistically significant difference between the groups for MCSF, CD68, and Ki67 expression (p>0.05). CONCLUSION: This study shows that although the markers MCSF, CD68, and Ki67 are expressed by localized and diffuse type TSGCT, their lack of specificity limits their use as a subsidiary immunohistochemical marker in the differential diagnosis of localized and diffuse type TSGCTs.
Diagnosis, Differential ; Giant Cell Tumors* ; Giant Cells* ; Macrophage Colony-Stimulating Factor ; Recurrence ; Sensitivity and Specificity